Lactobacillus fermentum PCC®

PCC Lfermentum_BW

First isolated from a Swedish female, Lactobacillus fermentum PCC® fulfils all the criteria as laid out by the joint FAO/WHO expert panel (2002). Besides a formally specified genus, species and strain, PCC® demonstates superior characteristics to successfully deliver clinically proven benefits.

PCC® remarkable adhesiveness favours its ability to colonize human tissues and continually produce metabolites, which mediate its beneficial effects.

Broad spectrum antagonistic effects
PCC® demonstrates marked inhibitory actions to the growth of pathogens (antagonistic effects) to a wide range of pathogens including E.coli, S.typhimurium, C. perfringens, Listeria, C. albicans, S.aureus, C. difficile and pseudomonas.

Resistance to stomach acids, bile salts and digestive enzymes (pepsin)
PCC® is proven to survive all of these harsh conditions as encountered in the digestive tract to arrive in the gut alive and viable to colonise.

Resistance to antibiotics
PCC® is resistant to several commonly used antibiotics (e.g amoxicillin + clavulanic acid, cefotaxime, ceftazidime, clindamycin, doxycycline, erythromycin, neomycin, tetracycline etc.) a highly desirable factor to help maintain a normal gastrointestinal microbiota during antibiotic therapy.

Resistance to nutrient limited conditions
Nutrient limited conditions are usual when enterobacteria proliferate. PCC® shows good survival even in such conditions unlike many strains of lactobacilli.

Specific clinical studies
The clinical studies carried out on PCC® are specific to this strain of probiotics and not extrapolated from class benefits of other Lactobacillus species.